Literature DB >> 27465900

Incidence of Lymph Node Metastases in Apparent Early-Stage Low-Grade Epithelial Ovarian Cancer: A Comprehensive Review.

Victor Lago1, Lucas Minig, Christina Fotopoulou.   

Abstract

OBJECTIVES: This study aimed to determine the incidence of lymph node (LN) metastases in presumed stage I-II low-grade epithelial ovarian cancer (EOC).
METHODS: Eligible studies were identified from MEDLINE and EMBASE (time frame, 2015-1975), that analyzed patients with clinical or radiologic presumed early-stage EOC who underwent a complete pelvic and para-aortic lymphadenectomy as part of their surgical staging. The number and site of dissected and involved LNs and the correlation with overall outcome are analyzed. The term low grade and also the older term well differentiated were used.
RESULTS: Thirteen of 978 identified studies were selected, and 13 of 75 studies were identified as eligible. A total of 1403 patients were analyzed in these 13 retrospective studies. The final International Federation of Gynecology and Obstetrics staging after completed surgical staging was I to II in 912 patients (65%). A total of 338 patients (24%) had grade 1 tumors whereas 473 patients (34%) had grade 2, and 502 patients (36%) had grade 3 tumors. Systematic lymphadenectomy was performed in 1159 patients (83%), whereof 1142 (82%) were pelvic and para-aortic LN dissections.In 185 patients (13%), an upstaging from an apparent clinical stage I-II to IIIC occurred because of LN involvement: 64 (35%) of the patients had only pelvic LNs metastases, 69 (37%) had only para-aortic LNs metastasis, and 51 (28%) had both a pelvic and para-aortic LN involvement. When analyzing only the patients with low-grade (grade 1 as the old classification) presumed early-stage disease (n = 273), only 8 patients (2.9%; range, 0-6.2) were identified with LNs metastases present.
CONCLUSIONS: The incidence of occult LN metastases in apparent early-stage low-grade EOC is 2.9% in a metaanalysis of retrospective studies. Future larger-scale prospectively assessed studies with established surgical quality of the LN dissection are warranted to establish the true incidence of LN metastasis in presumed early low-grade disease.

Entities:  

Mesh:

Year:  2016        PMID: 27465900     DOI: 10.1097/IGC.0000000000000787

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

Authors:  Pierluigi Benedetti Panici; Andrea Giannini; Margherita Fischetti; Francesca Lecce; Violante Di Donato
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

2.  Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway.

Authors:  Zhiying Qi; Lirong Yin; Yanying Xu; Fang Wang
Journal:  Mol Med Rep       Date:  2018-03-28       Impact factor: 2.952

3.  Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial.

Authors:  Victor Lago; Pilar Bello; Beatriz Montero; Luis Matute; Pablo Padilla-Iserte; Susana Lopez; Tiermes Marina; Marc Agudelo; Santiago Domingo
Journal:  Int J Gynecol Cancer       Date:  2020-05-23       Impact factor: 3.437

4.  How to evaluate the adequacy of staging for nodal-negative epithelial ovarian cancer? Use of nodal staging score.

Authors:  Yuan Xu; Haoran Li; Xiaoxia Tong; Yangyang Pang; Xiaojuan Tong; Luhong Li; Lei Cheng
Journal:  J Gynecol Oncol       Date:  2018-12-04       Impact factor: 4.401

5.  Systematic Lymph Node Dissection May Be Abolished in Patients With Apparent Early-Stage Low-Grade Mucinous and Endometrioid Epithelial Ovarian Cancer.

Authors:  Jiayu Chen; Jie Yin; Yan Li; Yu Gu; Wei Wang; Ying Shan; Yong-Xue Wang; Meng Qin; Yan Cai; Ying Jin; Lingya Pan
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

6.  Pre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer.

Authors:  Wei Wang; Jinyu Gu; Yanxia Liu; Xiaoxu Liu; Lei Jiang; Changfen Wu; Jing Liu
Journal:  Cancer Manag Res       Date:  2022-09-19       Impact factor: 3.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.